VISION-DMD

Designed to ensure a timely & cost-effective drug development for Duchenne muscular dystrophy

Search

  • The Project
    • Summary
    • Project Objectives
    • Project Consortium
    • Contact us
  • About DMD
    • What is DMD?
    • Living with Duchenne
    • Current treatment options
    • Duchenne boy’s stories
    • DMD Community
    • Standards of Care for Duchenne muscular dystrophy
  • Study Information
    • What is a clinical study?
    • Phase 2a clinical trial information
    • Phase 2a preliminary study results
    • Phase 2b clinical trial information
    • MRI – Magnetic Resonance Imaging
    • Biomarkers
    • Vamorolone study APP for boys
  • Drug Development
    • Development of Vamorolone
    • Vamorolone development programme
  • Funding Model
    • Patient Group Funders
    • What is Venture Philanthropy?
  • Resources
    • Relevant publications
      • VISION-DMD INFORMATION APP OVERVIEW
    • VISION-DMD Workshops
      • Workshop series: Standards of Care
      • Workshop series: Biomarkers and Imaging
    • Webinars and presentations
    • Press Releases
    • VISION-DMD project Interviews
      • An Interview with Andrea Smith – Clinical research project manager at TRiNDS
      • Interview with Jana Haberlová – Paediatric Neurologist at University Hospital Motol
      • Interview with Alex Johnson: a parent and patient foundation funder
    • VISION-DMD Project Newsletters
      • VISION-DMD newsletter sign up
    • VISION-DMD Poster presentations
    • Our privacy policy
  • enEnglish
    • nlNederlands
    • frFrançais
    • deDeutsch
    • itItaliano
    • esEspañol

Press Releases

August 2018: First Patient Enrolment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy

June 2018: Vamorolone Phase 2 top line press release

February 2018: ReveraGen BioPharma initiates VISION-DMD Phase 2b Study for Treatment of Duchenne Muscular Dystrophy

March 2017 : Vision-DMD update: ReveraGen BioPharma Receives FDA Fast Track Designation for Vamorolone for the Treatment of Duchenne Muscular Dystrophy

September 2016 :  ReveraGen BioPharma Inc initiates VISION-DMD Phase 2a Study for Treatment of Duchenne Muscular Dystrophy

Follow us on twitter

  • Twitter

EUFlag2020

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 667078.

To find out more about the project contact us at vision-dmd_team@ceratium.eu

VISION-DMD Copyright © 2019 · Log in

Multilingual WordPress with WPML

Cookies

This site uses cookies: Find out more.